Story

Summit Therapeutics Stock Gains on Partner's Positive Cancer Drug Trial Data

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20261 min read
Summit Therapeutics Stock Gains on Partner's Positive Cancer Drug Trial Data
Text size
Background

Summit Therapeutics Inc. (NASDAQ:SMMT) shares climbed as much as 7.75% on Wednesday after its partner, Akeso Inc., reported positive topline results from a Phase III study of the cancer drug ivonescimab.

Trial Meets Primary Endpoint

Akeso announced that its HARMONi-GI1 study in China met its primary endpoint. The trial demonstrated that ivonescimab combined with chemotherapy achieved a statistically significant superiority in overall survival (OS) compared to the current standard of care, durvalumab plus chemotherapy, for the first-line treatment of advanced biliary tract cancer (BTC).

The 682-patient study also successfully met its key secondary endpoints, which included progression-free survival (PFS) and objective response rate (ORR). Ivonescimab is already approved in China for certain non-small cell lung cancer indications but remains an investigational drug in Summit's licensed territories, including the U.S. and Europe. Akeso noted that detailed results will be presented at a future medical congress.

Sample IUX Markets – In-articleAd

Analyst Commentary and Market Impact

Analysts highlighted the data's potential implications beyond the biliary tract cancer market. Guggenheim analyst Brad Canino reiterated a Buy rating and a $38.00 price target, stating that the result adds to the drug's "consistency of effect." In a note to clients, Canino wrote, "we think the lung read-through is more important than the new unlocked BTC commercial opportunity," suggesting the data reinforces the potential for success in the much larger lung cancer market.

Other analysts were more cautious pending full data. H.C. Wainwright's Mitchell S. Kapoor maintained a Neutral rating, commenting that while the results establish activity, the magnitude of the survival benefit remains unclear without the specific overall survival hazard ratio. Kapoor noted that H.C. Wainwright assigns "no ex-China BTC economics" at this time, with the next major catalyst for the stock likely being lung cancer data expected in the second half of 2026.

Read next

More on Stocks
Back to latest news

LATEST